CLEVELAND, Aug. 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Dartmouth-Hitchcock Health in New Hampshire has begun patient treatments with the MRIdian® MRI-Guided Therapy ...
CLEVELAND, Feb. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Edogawa Hospital in Tokyo is the first hospital in Japan to treat patients with the MRIdian Linac System.
CLEVELAND, Aug. 11, 2022 /PRNewswire/ -- ViewRay, Inc. (MRXC) (NASDAQ: VRAY) today announced that the National Cancer Center Hospital (NCCH) of Japan has upgraded its original Cobalt MRIdian® ...
CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) in Kaohsiung City, Taiwan has begun patient ...
CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian ® ...
ViewRay's MRIdian Linac system received FDA approval in February 2017. The company's system has received positive reviews from oncologists and hospitals. We view its new system as a game changer in ...
Retrospective analysis shows MRIdian's small treatment margins enabled by adaptation and real-time tracking and automated beam control may allow for ablative radiation with minimal toxicity in hard to ...
The market introduction of the MR-Linac technology improves the patient care via the real-time imaging of the targeted PTVs. Conventional Water Phantoms with ferromagnetic material become prohibited ...
The market introduction of the MR-Linac technology improves the quality of patient care via the real-time imaging of the targeted PTVs. The online control of the PTVs permits the gating process of the ...
Viewray Inc. received FDA clearance for the Mridian Linac system, a device that allows clinicians to visualize in real time the movement of tumors and organs during radiation treatment. The Oakwood, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results